# Influence of CYP2C19 Polymorphism on PK/PD of Omeprazole

> **NCT02299687** · PHASE1 · COMPLETED · sponsor: **Seoul National University Hospital** · enrollment: 24 (actual)

## Conditions studied

- Stomach Ulcer

## Interventions

- **DRUG:** Omeprazole

## Key facts

- **NCT ID:** NCT02299687
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2014-12
- **Final completion:** —
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2015-01-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02299687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02299687, "Influence of CYP2C19 Polymorphism on PK/PD of Omeprazole". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02299687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*